ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1900

Performance of the Detect Protocol for Pulmonary Arterial Detection in Systemic Sclerosis Patients in Clinical Practice

Otto Martin Olivas Vergara1, Beatriz E. Joven1, Belen Diaz Anton2, Carmen Jiménez2, Maria Martin Lopez3, Pilar Escribano2 and Patricia E. Carreira1,2, 1Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 2Multidisciplinary Pulmonary Hypertension Unit. Hospital Universitario 12 de Octubre, Madrid, Spain, 3RHEUMATOLOGY, Hospital Universitario 12 de Octubre, Madrid, Spain

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To analyze the usefulness of the DETECT protocol (1) for the prediction of pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) in routine clinical practice in a systemic sclerosis (SSc) clinic.

Methods: All patients with SSc seen in the Rheumatology Department with a right heart cathetherization (RHC) performed between Jan 1998 and May 2015 and with an echocardiography available within 3 months of the RHC were included. The two steps DETECT score was retrospectively obtained. Receiver Operating Characteristic (ROC) curve and area under the curve (AUC) were calculated for the ability of DETECT score to identify PH and PAH patients. Associations of clinical and RHC data, DETECT score, and disparity between PH and PAH diagnosis and DETECT score, were analysed.

Results: The study included 61patients (82% women, 75% limited cutaneous (lc) SSc, 57±15 y). Mean disease duration from first non-Raynaud symptom was 11±10 years. Pulmonary hypertension (PH) was confirmed by RHC in 50 (82%) patients, of those 38 (62%) had PAH. Other causes of PH were pulmonary fibrosis in 10 patients, with associated myocardiopathy in 3. Other 2 patients had non SSc associated valvulopathy. ROC curve showed an elevated discriminatory capacity of the DETECT score for prediction of PH and PAH, with AUC of 0.930 and 0.867 respectively. Disparity between PH in RHC and DETECT score was present in 10 patients. Only one patient, with severe hypertrophic cardiomyopathy and secondary PH had a negative DETECT score. The other 9 patients, 6 with cardiopathy (3 valvulopathy, 3 SSc related cardiomyopathy) had a positive DETECT score but did not present PH in RHC. Other 11 patients presented PH of other causes (1 non SSc valvulopathy, 9 PF, 4 also with SSc cardiomyopathy) Disparity between PH in RHC and DETECT score was more frequent in the presence of any cardiopathy (p<.002), absence of right axis deviation (p<.011) and higher tricuspid jet velocity (TJV)(p<.0001). Disparity between PAH diagnosis and DETECT score was more frequent in males (p=.011), with  dcSSc (p=.031), PF (p<.0001) or cardiopathy (p<.0001), higher TJV (p<. 001), lower FVC (p<.001), higher uric acid (p=.007) and less frequent  in the absence of right axis deviation (p=.0026) and in ACA+ patients (p=.003). The results were similar when only the 33 patients who would have been included in the DETECT study (disease duration higher than 3 years and DLCO lower than 60%) were analyzed. When the 28 patients who would not have been included in the DETECT study (less than 3 years of disease duration or DLCO higher than 60%), only the presence of dcSSc (p=.013) or cardiomyopathy (p=.013) were associated with disparity between PH in RHC and DETECT score.

Conclusion: The DETECT algorithm performs very well in a routine clinical setting for early detection of PAH and also of PH or other causes in SSc patients. Our results suggest that the algorithm would not perform as well in patients with any type of cardiopathy.

(1) Coghlan JG, Denton CP et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. ARD 2014;73:1340-9


Disclosure: O. M. Olivas Vergara, None; B. E. Joven, None; B. Diaz Anton, None; C. Jiménez, None; M. Martin Lopez, None; P. Escribano, None; P. E. Carreira, None.

To cite this abstract in AMA style:

Olivas Vergara OM, Joven BE, Diaz Anton B, Jiménez C, Martin Lopez M, Escribano P, Carreira PE. Performance of the Detect Protocol for Pulmonary Arterial Detection in Systemic Sclerosis Patients in Clinical Practice [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/performance-of-the-detect-protocol-for-pulmonary-arterial-detection-in-systemic-sclerosis-patients-in-clinical-practice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-the-detect-protocol-for-pulmonary-arterial-detection-in-systemic-sclerosis-patients-in-clinical-practice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology